“益神颗粒”对于心脾两虚型失眠患者的疗效观察与安全性评价

为观察院内自制制剂益神颗粒治疗心脾两虚型失眠患者临床疗效并进行安全性评价,本研究选取了188例心脾两虚型失眠患者,分为治疗组及对照组,观察治疗组(益神颗粒组)及对照组(安慰剂组)在治疗前、治疗2周后、治疗4周后及治疗完成后随访1周的睡眠SPIEGEL量表、中医症候量表、汉密尔顿抑郁量表、汉密尔顿焦虑量表变化及血常规、肝肾功能、心电图的改变。研究发现治疗2周、4周后益神颗粒组的睡眠SPIEGEL量表、中医症候量表、汉密尔顿抑郁量表、汉密尔顿焦虑量表评分均明显低于安慰剂组,差异有统计学意义(p0.05);血液指标皆在正常范围内,异常心电图表现发生率在治疗前后无统计学差异(p0.05)。研究结果表明益神颗粒对于心脾两虚型失眠患者具有良好的临床疗效且无明显不良反应,具有进一步推广应用的临床价值。     

西酞普兰联合利培酮治疗难治性抑郁症的近期临床疗效观察

目的:观察西酞普兰联合利培酮治疗难治性抑郁症的近期临床疗效,探讨提高难治性抑郁症近期临床疗效的药物治疗方案方法:选择难治性抑郁症患者86例,随机均分为对照组与观察组,对照组给予常规西酞普兰治疗,观察组给予西酞普兰联合利培酮治疗,比较两组患者治疗第2周、第4周、第6周汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评分,比较两组患者治疗第6周的临床疗效.结果:观察组近期临床疗效好于对照组,HAMD评分、HAMA评分和临床疗效比较,差异具有统计学意义(P＜0.05);TESS评分比较,差异无统计学意义(P＞0.05).结论:药物治疗难治性抑郁症时,应选择西酞普兰联合利培酮治疗,可提高近期临床疗效,且不加重用药不良反应.     

螺环酮联合帕罗西汀治疗焦虑症的疗效及安全性分析

目的:研究螺环酮联合帕罗西汀治疗焦虑症的疗效及其安全性。方法:选取2009年1月至2013年8月我院收治的符合诊断标准的焦虑症患者244例,按照知情同意原则随机分为治疗组(122例)和对照组(122例),治疗组给予丁螺环酮联合帕罗西汀治疗,对照组仅给予螺环酮治疗。治疗10周后,运用汉密尔顿焦虑量表(HAMA)及Montgomery-Asberg抑郁量表(MADS)评价疗效,运用治疗过程中不良反应症状量表(TESS)评价其安全性,比较两组患者的疗效及安全性。结果:治疗后两组的HAMA及MADS评分均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P0.05);两组TEES评分在治疗第2、4、6、8、10周末均无统计学差异(P0.05)。结论:螺环酮联合帕罗西汀在治疗焦虑症时可提高疗效,且安全性高,可考虑在临床推广。     

腹针疗法治疗冠心病介入术后合并焦虑抑郁障碍患者疗效及对患者焦虑、躯体症状的影响

摘要 目的：探讨腹针疗法治疗冠心病介入术后合并焦虑抑郁障碍患者疗效及对焦虑、躯体症状的影响。方法：选择2021年8月-2022年5月在广东省中医院诊治的冠心病介入术后合并焦虑抑郁障碍患者120例作为研究对象,根据1:1平行对照原则把患者分为试验组与对照组各60例。对照组给予常规治疗,试验组在对照组治疗的基础上给予腹针疗法治疗,试验组与对照组都治疗观察4周。结果：试验组与对照组治疗后的焦虑与抑郁评分明显低于治疗前,试验组明显低于对照组（P<0.05）。试验组与对照组治疗后的心绞痛积分明显高于治疗前,试验组明显高于对照组（P<0.05）。治疗后,两组中医症候积分较治疗前低,试验组也明显低于对照组（P<0.05）。试验组治疗期间的便秘、嗜睡、头晕、心动过速等不良反应发生率为3.3 %,对照组为21.7 %,试验组与对照组对比有明显差异（P<0.05）。结论：腹针疗法治疗冠心病介入术后合并焦虑抑郁障碍患者能促进缓解焦虑抑郁症状还可减少不良反应,改善心绞痛症状,降低中医症候积分。     

认知疗法联合舍曲林治疗产后抑郁症患者的临床疗效研究*

摘要目的：探讨认知疗法合并舍曲林治疗产后抑郁症患者的临床疗效。方法：将本院2011 年10 月至2012 年7 月收治的76 例 产后抑郁症患者按随机数字表法分为认知疗法合并舍曲林治疗组(试验组,38 例)和舍曲林单独治疗组(对照组,38 例),进行临床 随机双盲对照试验,采用17 项汉密尔顿抑郁量表(Hamilton Depression Rating Scale,HAMD)、临床整体量表- 疗效总评估量表 (Clinical Global Impression,CGI) 评价和比较两组的临床疗效。结果：(1) 试验组的有效率显著高于对照组,差异有统计学意义 [92.11%vs 81.58 %),P<0.01],试验组第2、3 阶段的临床有效率均显著高于对照组,差异有统计学意义(P<0.05)。(2) 与治疗前相 比,两组患者治疗后的HAMD、CGI-SI 总分均降低,差异有统计学意义(P<0.01);治疗第1、2、3 阶段,试验组HAMD、CGI-SI 减分 值均显著高于对照组,差异有统计学意义(P<0.05)。结论：认知疗法联合舍曲林治疗产后抑郁症的短期治疗内疗效显著优于舍曲 林单独治疗。     

艾司西酞普兰联合心理疗法对焦虑症患者睡眠质量、生活质量和血清神经递质水平的影响

目的:探讨艾司西酞普兰联合心理疗法对焦虑症患者睡眠质量、生活质量和血清神经递质水平的影响。方法:选取2017年7月~2020年3月期间我院收治的焦虑症患者117例,随机分为对照组58例和研究组59例,对照组给予艾司西酞普兰治疗,研究组在对照组的基础上联合心理疗法,对比两组疗效、汉密尔顿焦虑量表(HAMA)、匹兹堡睡眠质量指数量表(PSQI)及健康调查简表(SF-36)评分、血清神经递质[5-羟色胺(5-HT)、去甲肾上腺素(NE)、髓过氧化物酶(MPO)和神经肽(NPY)]水平及不良反应。结果:治疗8周后,研究组的临床总有效率为88.14%(52/59),明显高于对照组的70.69%(41/58)(P<0.05)。研究组治疗8周后血清MPO水平低于对照组,5-HT、NE、NPY水平高于对照组(P<0.05)。研究组治疗8周后HAMA、PSQI量表评分低于对照组(P<0.05)。研究组治疗8周后精神健康、生理机能、躯体疼痛、社会功能、情感职能、活力、生理职能、健康状况评分均高于对照组(P<0.05)。两组不良反应发生率对比差异无统计学意义(P>0.05)。结论:艾司西酞普兰联合心理疗法治疗焦虑症患者疗效及安全性均较好,可有效改善患者焦虑症状、睡眠质量及生活质量,同时还可有效调节血清神经递质水平。     

头穴丛刺治疗抑郁症的临床疗效观察

目的:观察头穴丛刺对于抑郁症患者的临床疗效。方法:将60例纳入患者采用随机对照法,随机分为治疗组与对照组,治疗组予以针刺及口服用药治疗,日1次,4星期为1疗程;对照组仅给予口服用药治疗,日1次,4星期为1疗程。采用汉密尔顿抑郁量表(HAMD)进行评估。结果:经1疗程后,治疗组临床疗效及HAMD评分明显优于对照组疗效﹙p0.05﹚头穴丛刺对于抑郁症患者有较显著疗效。     

西酞普兰联合利培酮治疗难治性抑郁症的近期临床疗效观察

目的：观察西酞普兰联合利培酮治疗难治性抑郁症的近期临床疗效,探讨提高难治性抑郁症近期临床疗效的药物治疗方案方法：选择难治性抑郁症患者86例,随机均分为对照组与观察组,对照组给予常规西酞普兰治疗,观察组给予西酞普兰联合利培酮治疗,比较两组患者治疗第2周、第4周、第6周汉密尔顿抑郁量表（HAMD）、汉密尔顿焦虑量表（HAMA）和副反应量表（TESS）评分,比较两组患者治疗第6周的临床疗效。结果：观察组近期临床疗效好于对照组,HAMD评分、HAMA评分和临床疗效比较,差异具有统计学意义（P〈0.05）;TESS评分比较,差异无统计学意义（P〉0.05）。结论：药物治疗难治性抑郁症时,应选择西酞普兰联合利培酮治疗,可提高近期临床疗效,且不加重用药不良反应。     

认知疗法联合舍曲林治疗产后抑郁症患者的临床疗效研究

目的：探讨认知疗法合并舍曲林治疗产后抑郁症患者的临床疗效。方法：将本院2011年10月至2012年7月收治的76例产后抑郁症患者按随机数字表法分为认知疗法合并舍曲林治疗组（试验组,38例）和舍曲林单独治疗组（对照组,38例）,进行临床随机双盲对照试验,采用17项汉密尔顿抑郁量表（HamiltonDepressionRatingScale,HAMD）、临床整体量表一疗效总评估量表（ClinicalGlobalImpression,CGI）评价和比较两组的临床疗效。结果：（1）试验组的有效率显著高于对照组,差异有统计学意义[92．11％VS81．58％）,P〈0．01],试验组第2、3阶段的临床有效率均显著高于对照组,差异有统计学意义（P〈0．05）。（2）与治疗前相比,两组患者治疗后的HAMD、CGI．SI总分均降低,差异有统计学意义（P〈0．01）;治疗第1、2、3阶段,试验组HAMD、CGI—SI减分值均显著高于对照组,差异有统计学意义（P〈0．05）。结论：认知疗法联合舍曲林治疗产后抑郁症的短期治疗内疗效显著优于舍曲林单独治疗。     

甲状腺功能减退患者实施快乐因子刺激干预的临床观察

目的:探讨快乐因子刺激干预对甲状腺功能减退患者进行护理的临床效应.方法:选取52例甲状腺功能减退患者,随机分为对照组和试验组,各26例.对照组给予常规治疗及护理,试验组在对照组的基础上采用快乐因子刺激进行护理干预,比较两组患者服药依从性及治疗效果,并采用汉密尔顿抑郁量表(HAMD)与汉密尔顿焦虑量表(HAMA)对两组患者进行测评.结果:试验组实施干预后,HAMD与HAMA评分明显降低,与对照组相比,差异有统计学意义(P＜0.05);试验组患者对治疗的依从性明显好于对照组(P＜0.05),试验组治疗效果优于对照组(P＜0.05).结论:快乐因子刺激干预能有效提高甲减患者的正性情绪,提高服药依从性,增强治疗效果.     

A Unique Protease Cleavage Site Predicted in the Spike Protein of the Novel Pneumonia Coronavirus (2019-nCoV) Potentially Related to Viral Transmissibility

正Dear Editor,In December 2019, a novel human coronavirus caused an epidemic of severe pneumonia(Coronavirus Disease 2019,COVID-19) in Wuhan, Hubei, China(Wu et al. 2020; Zhu et al. 2020). So far, this virus has spread to all areas of China and even to other countries. The epidemic has caused 67,102 confirmed infections with 1526 fatal cases     

Curcuminoids as inhibitors of thioredoxin reductase: A receptor based pharmacophore study with distance mapping of the active site

Curcumin is the yellow pigment of turmeric that interacts irreversibly forming an adduct with thioredoxin reductase (TrxR), an enzyme responsible for redox control of cell and defence against oxidative stress. Docking at both the active sites of TrxR was performed to compare the potency of three naturally occurring curcuminoids, namely curcumin, demethoxy curcumin and bis-demethoxy curcumin. Results show that active sites of TrxR occur at the junction of E and F chains. Volume and area of both cavities is predicted. It has been concluded by distance mapping of the most active conformations that Se atom of catalytic residue SeCYS498, is at a distance of 3.56 from C13 of demethoxy curcumin at the E chain active site, whereas C13 carbon atom forms adduct with Se atom of SeCys 498. We report that at least one methoxy group in curcuminoids is necessary for interation with catalytic residues of thioredoxin. Pharmacophore of both active sites of the TrxR receptor for curcumin and demethoxy curcumin molecules has been drawn and proposed for design and synthesis of most probable potent antiproliferative synthetic drugs.     

The structure, reproduction and taxonomy of Vidalia and Osmundaria (Rhodophyta, Rhodomelaceae)

Comprises species occurring mostly in subtidal habitats in tropical, subtropical and warm-temperate areas of the world. An analysis of the type species, V. spiralis (Sonder) Lamouroux ex J. Agardh, a species from Australia, establishes basic characters for distinguishing species in the genus. These characters are (1) branching patterns of thalli, (2) flat blades that may be spiralled on their axis, (3) width of the blade, (4) primary or secondary derivation of sterile and fertile branchlets and (5) position of sterile and fertile branchlets on the thalli. Application of the latter two characters provides an important basic method for separation of species into three major groups. Osmundaria , a genus known only in southern Australia, was studied in relation to Vidalia , and its separation from the Vidalia assemblage is not accepted. Species of Vidalia therefore are transferred to the older genus name, Osmundaria. Two new species, Osmundaria papenfussii and Osmundaria oliveae are described from Natal. Confusion in the usage of the epithet, Vidalia fimbriala Brown ex Turner has been clarified, and Vidalia gregaria Falkenberg, described as an epiphyte on Osmundaria pro/ifera Lamouroux, is revealed to be young branches of the host, Osmundaria prolifera.     

New or rare chromosome counts in Artemisia L. (Asteraceae, Anthemideae) and related genera from Kazakhstan

Fifteen chromosome counts of six Artemisia taxa and one species of each of the genera Brachanthemum, Hippolytia, Kaschgaria, Lepidolopsis and Turaniphytum are reported from Kazakhstan. Three of them are new reports, two are not consistent with previous counts and the remainder are confirmations of very scarce (one to four) earlier records. All the populations studied have the same basic chromosome number, x = 9, with ploidy levels ranging from 2x to 6x. Some correlations between ploidy level, morphological characters and distribution are noted.     

Comparative morphology of the carpel in the Liliaceae: Hewardieae, Petrosavieae, and Tricyrteae

The young pistils in the melanthioid tribes, Hewardieae, Petrosavieae and Tricyrteae, are uniformly tricarpellate and syncarpous. They lack raphide idioblasts. All are multiovulate, with bitegmic ovules. The Petrosavieae are marked by the presence of septal glands and incomplete syncarpy. Tepals and stamens adhere to the ovary in the Hewardieae and the Petrosavieae but not in the Tricyrteae. Two vascular bundles occur in the stamens of the Hewartlieae and Tricyrtis latifolia. Ventral bundles in the upper part of the ovary of the Hewardieae are continuous with compound septal bundles and placental bundles in the lower part. Putative ventral bundles occur in the alternate position in the Tricyrteae and putative placental bundles in the opposite. position in the Petrosavieae. The dichtomously branched stigma in each carpel of the Tricyrteae is supplied by a bifurcated dorsal bundle.     

肝癌中HBV和HCV基因和抗原的分布及意义

采用原位分子杂交方法检测HCV RNA及HBV X基因;采用免疫组织化学方法研究HCV核心抗原,非结构区C33c抗原及HBxAg在肝细胞肝癌中的定位及分布.结果表明(1)HCV RNA、HBV X基因在肝细胞肝癌组织检出率分别为40%(55/136)和82%(112/136).HCV RNA定位于癌细胞的胞浆内,阳性细胞呈散在、灶状及弥漫分布三种形式;HBV X基因在肝癌细胞中的分布呈胞浆型、核型及核浆型,阳性细胞也呈上述三种分布形式;(2)HCV C33c抗原、核心抗原在肝细胞肝癌中的阳性率为81%(133/164)及86%(141/164).C33c抗原定位于癌细胞及肝细胞的胞浆内;核心抗原既定位于癌细胞核中,又可定位于胞浆中.C33c抗原阳性细胞以灶状分布为主;而核心抗原阳性细